<DOC>
	<DOCNO>NCT00004082</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine docetaxel , carboplatin , gemcitabine treat patient previously untreated , newly diagnose epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Previously Untreated , Newly Diagnosed Epithelial Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose docetaxel , carboplatin , gemcitabine patient previously untreated , newly diagnose , high-risk epithelial cancer mullerian origin . OUTLINE : This dose-escalation study docetaxel gemcitabine . Patients receive docetaxel IV 30 minute gemcitabine IV 30 minute day 1 8 . Carboplatin IV administer 30 minute day 1 . Treatment repeat every 21-28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-5 patient receive escalate dos docetaxel gemcitabine maximum tolerate dose determine . The MTD define dose precede 2 3 2 5 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 1.5-2 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose , highrisk epithelial tumor mullerian origin , include : Ovarian epithelial cancer Peritoneal papillary serous cancer Primary fallopian tube cancer Endometrial cancer Highrisk define : Any amount gross residual disease remain time initial debulking surgery AND/OR Any radiographic physical exam evidence disease surgery AND/OR Disease outside abdomen ( e.g. , malignant pleural effusion ) AND/OR Parenchymal liver , spleen , lung metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 2 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN SGOT SGPT great 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 35 mL/min Cardiovascular : Acceptable cardiac exam No active cardiac ischemia Pulmonary : Acceptable pulmonary exam No active pulmonary infection compromise Other : Not pregnant nursing No peripheral neuropathy grade 2 great No debilitate medical psychiatric condition would preclude study No malignancy within past 3 year except limited stage basal squamous cell skin cancer carcinoma situ cervix No evidence infection Adequate bowel function , oral intake , wound heal ability PRIOR CONCURRENT THERAPY : Biologic therapy : No prior cytokine therapy epithelial tumor mullerian origin Chemotherapy : No 1 prior chemotherapy regimen epithelial tumor mullerian origin At least 3 year since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy Surgery : See Disease Characteristics At least 7 day since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>